Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282476 · ClinicalTrials.gov registry record · Phase 2
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01282476: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01282476 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282476, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory studies. However, it is not known if it will show the same activity in humans. Panobinostat has been given to participants with various types of cancers, including DLBCL, in previous research studies. In this study panobinostat will be given with the the antibody rituximab, which is FDA approved to be given with chemotherapy in DLBCL.
Interventions
- DRUG Panobinostat with Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282476
The ClinicalTrials.gov registry entry for NCT01282476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panobinostat with Rituximab is the first listed.
NCT01282476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282476 about?
NCT01282476 is a clinical study titled "Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma". Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory studies. However, it is not known if it will show the same activity in humans. Panobinostat has been given to participant...
What is the current status of trial NCT01282476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-06. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01282476?
The interventions under investigation include: Panobinostat with Rituximab (DRUG).
Who is sponsoring clinical trial NCT01282476?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.